Pharmacoscopy for Patients With Refractory Primary Brain Tumors

Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.

Trial Details

NCT ID
NCT06804655
Phase
PHASE2
Sponsor
University of Zurich
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Pharmacoscopy 1.0
Locations (sample)
  • Basel, Basel-Landschaft, Switzerland
  • Sankt Gallen, Canton of St. Gallen, Switzerland|47.42391,9.37477
  • Zurich, Canton of Zurich, Switzerland|47.36667,8.55

Key Eligibility Criteria

  • Age 18 years or older on day of signing informed consent, female or male.
  • Refractory glioblastoma, isocitrate dehydrogenase (IDH)-mutant astrocytoma or oligodendroglioma, histone-mutant glioma, ependymoma, medulloblastoma…
  • Karnofsky performance status of 60 or more
  • Life expectancy \>12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →